About the Authors
- Pedro Henrique Papotto
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Eliana Blini Marengo
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Luiz Roberto Sardinha
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Karina Inácio Carvalho
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Ana Eduarda Zulim de Carvalho
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Sheyla Castillo-Mendez
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Carina Calixto Jank
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Bernard Vanhove
-
Affiliation OSE Immunotherapeutics SA, Nantes, France
- Anna Carla Goldberg
-
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
- Luiz Vicente Rizzo
-
* E-mail: lvrizzo@einstein.br
Affiliation Hospital Israelita Albert Einstein, São Paulo, Brazil
Competing Interests
BV is employee and shareholder of OSE Immunotherapeutics, a company developing CD28 antagonists. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: LVR BV ACG EBM PHP. Formal analysis: PHP KIC LRS. Investigation: PHP EBM AEZC CCJ SC-M. Methodology: LVR ACG LRS KIC EBM PHP. Project administration: ACG. Resources: BV. Supervision: LVR BV. Writing – original draft: LVR ACG PHP EBM.